Moreover, combinations with PI3K pathway inhibitors, e.g. rapamycin and everolimus, and with tamoxifen, trastuzumab, and erlotinib have revealed synergistic effects in breast cancer treatment [166–171]. The gene discussed is PIK3CA; the disease is breast carcinoma.